Numerous studies have reported the vast medicinal values of proteins from mushrooms. The present study aimed to investigate the potential of protein extracts from the sclerotium of Pleurotus tuber-regium (Fr.) Singer for antitumor activities against a breast cancer cell line. Protein from P. tuber-regium sclerotium was fractionated using ammonium sulphate at concentrations of 30%, 60%, and 90% and designated as PS30, PS60, and PS90, respectively. All protein extracts were assessed for cytotoxicity toward breast cancer cell line MDA-MB-231 and normal lung fibroblast cell line MRC-5 in the MTT assay. The ability of the protein extracts to inhibit cellular migration was evaluated using the antimigration assay. The most promising protein extract against MDA-MB-231 cells was PS60, with a half-maximal inhibitory concentration of 0.75 ± 0.57 μg/mL and a selectivity index of 14.00. Cytotoxicity and antimigration effects on cancer cells were best exhibited by PS60, with absolute migration capability values between 5.4142 ± 0.6916 and 5.6581 ± 0.2015 nm/h. PS60 was shown to exert cytotoxic effects associated with the induction of apoptosis and cell cycle arrest in MDA-MB-231 cells at G1/G0 and S phase. In conclusion, PS60 protein of P. tuber-regium sclerotium has good potential to be developed into a novel antitumor drug against breast cancer.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1615/IntJMedMushrooms.2021041548 | DOI Listing |
Discov Oncol
January 2025
Department of General Surgery, The Second Affiliated Hospital of the Air Force Medical University, Xi'an, 710038, China.
A common digestive system cancer with a dismal prognosis and a high death rate globally is breast cancer (BRCA). BRCA recurrence, metastasis, and medication resistance are all significantly impacted by cancer stem cells (CSCs). However, the relationship between CSCs and the tumor microenvironment in BRCA individuals remains unknown, and this information is critically needed.
View Article and Find Full Text PDFBreast Cancer Res Treat
January 2025
Department of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian , China.
Purpose: Age stratification influences the clinicopathological features and survival outcomes of breast cancer. We aimed to understand the effect of age on gene variants in young Chinese women with breast cancer compared with those from The Cancer Genome Atlas (TCGA).
Methods: Enrolled patients ≤ 40 years old (N = 370) underwent germline or somatic genetic testing using a 32-gene hereditary cancer panel at Fujian Union Hospital.
Breast Cancer Res Treat
January 2025
Division of Medical Oncology, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, 8700 Beverly Blvd., Los Angeles, CA, 90048, USA.
Purpose: There is an increasing incidence of young breast cancer (YBC) patients with uncertainty surrounding the factors and patterns that are contributing.
Methods: We obtained characteristics and survival data from 206,156 YBC patients (≤ 40 years of age) diagnosed between 2005 and 2019 from the National Cancer Database (NCDB). Patients were subdivided into two comparison groups based on year of diagnosis (2005-2009, Old vs.
Adv Sci (Weinh)
January 2025
Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, 110122, China.
Hydrogen sulfide (HS)-mediated protein S-sulfhydration has been shown to play critical roles in several diseases. Tumor-associated macrophages (TAMs) are the predominant population of immune cells present within solid tumor tissues, and they function to restrict antitumor immunity. However, no previous study has investigated the role of protein S-sulfhydration in TAM reprogramming in breast cancer (BC).
View Article and Find Full Text PDFAnn Surg Oncol
January 2025
Department of Surgery, Duke University Medical Center, Durham, NC, USA.
Background: Bilateral risk-reducing mastectomies (RRMs) have been proven to decrease the risk of breast cancer in patients at high risk owing to family history or having pathogenic genetic mutations. However, few resources with consolidated data have detailed the patient experience following surgery. This systematic review features patient-reported outcomes for patients with no breast cancer history in the year after their bilateral RRM.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!